GlaxoSmithKline is pretty proud of its rotacaps and its blow-fill-seal lines at its packaging plant in the Melbourne, Australia, suburb of Boronia. Its tablet line, not so much, and the drugmaker will eliminate that line and lay off about a third of the workforce at the facility.
Ranbaxy Laboratories wants the world to know it is not the same company it was when it lied to the FDA and tried to hide serious manufacturing and drug quality problems that led to last week's felony convictions for the Indian drugmaker. Today it laid out many of the of the improvements it has made since the fraud, like adding independent members to its board of directors.
Another Big Pharma CEO is having a pep talk with employees about manufacturing lapses and the need to reflect on quality.
A worker at an Amgen research facility in South San Francisco has been hospitalized after a "flash fire" involving hazardous materials.
Problems at a Janssen over-the-counter plant in Korea have gone from unfortunate to very serious now that authorities there intend to pursue criminal charges. This tack means Kim Oak-yeon, CEO of the Johnson & Johnson ($JNJ) subsidiary in South Korea, faces up to three years in jail if convicted.
The FDA cast a wider net this year as it sent inspectors into what it called 30 "high risk" compounding pharmacies, those that made sterile drugs that can easily be contaminated. The attack has had a pronounced effect on the number of recalls the agency has ordered.
An active pharmaceutical ingredient facility in Cork County, Ireland, has been targeted for closure next year, although Pfizer hopes its can save the 136 jobs there by selling it to another drugmaker.
Pharmaceuticals are known to get into waterways by a variety of routes. Some are flushed down toilets by patients, others originate from production-plant wastewater. Yet a new study has found chemicals in lakes far from any known sources, raising the possibility of airborne transit.
Having already had its plans for wind turbines rejected, GSK turned to tidal power, only to have that proposal dismissed too. Yet the company is still trying.
Biotech Dendreon, the maker of prostate cancer vaccine Provenge, continues to struggle with earnings even after undertaking a restructuring program which included unloading one of its manufacturing plants.